Banque Pictet & Cie Sa Biomarin Pharmaceutical Inc Transaction History

Banque Pictet & Cie Sa

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$87.74 - $117.27 $643,660 - $860,292	-7,336 Reduced 39.17%	11,394 $1.11 Million
Q4 2022 Feb 06, 2023	SELL	$80.93 - $108.63 $406,268 - $545,322	-5,020 Reduced 21.14%	18,730 $0
Q3 2022 Nov 10, 2022	SELL	$82.16 - $96.94 $505,859 - $596,859	-6,157 Reduced 20.59%	23,750 $2.01 Billion
Q2 2022 Aug 08, 2022	BUY	$71.48 - $86.85 $70,622 - $85,807	988 Added 3.42%	29,907 $2.48 Million
Q1 2022 May 04, 2022	BUY	$74.28 - $92.69 $2.15 Million - $2.68 Million	28,919 New	28,919 $2.23 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.